Premium
Current status of biomarkers in head and neck cancer
Author(s) -
Chang Steven S.,
Califano Joseph
Publication year - 2008
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21023
Subject(s) - medicine , biomarker , oncology , cancer , molecular biomarkers , head and neck cancer , head and neck , pathology , surgery , biology , biochemistry
As our understanding of HNSCC increases so has biomarker development. HPV16 integration is a significant marker of favorable prognosis and response to therapy for HNSCC. EGFR‐amplification and overexpression is a poor‐prognostic indicator. For premalignant lesions, LOH of 3p&9p21 loci confers an elevated risk of malignant transformation. As molecular targets are identified, these will be candidates for biomarkers for detection, diagnosis, prognosis, and therapy. Validation of these biomarkers requires demonstration of independence of significance beyond known biomarkers. J. Surg. Oncol. 2008;97:640–643. © 2008 Wiley‐Liss, Inc.